Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

Figure 5

Effects of RAD001, gefitinib or sunitinib versus drug combination on kidney cancer proliferation in vitro. A498, Caki-1 or KTC-26 cells were treated with 1 nM RAD001, 1 μM gefitinib or 1 μM sunitinib, applied alone or in combination. Controls remained untreated. Cells were then counted after a further 24, 48 and 72 h using the MTT dye reduction assay. One representative of 6 experiments is shown. * indicates significant difference to controls (p < 0.05).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us